<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-8123</journal-id>
<journal-title><![CDATA[Revista Colombiana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Colomb.Reumatol.]]></abbrev-journal-title>
<issn>0121-8123</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-81232023000200150</article-id>
<article-id pub-id-type="doi">10.1016/j.rcreu.2021.11.004</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Ensayos clínicos: conceptos generales e interpretación]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical trials: General concepts and interpretation]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castaño González]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Puerta]]></surname>
<given-names><![CDATA[José A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Artmédica  ]]></institution>
<addr-line><![CDATA[Medellín Antioquia]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Clínic, Barcelona Servicio de Reumatología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>30</volume>
<numero>2</numero>
<fpage>150</fpage>
<lpage>155</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-81232023000200150&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-81232023000200150&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-81232023000200150&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Existen diferentes tipos de diseños de ensayos clínicos que sirven a propósitos específicos y dependerán tanto de la naturaleza de la enfermedad reumatológica como de las características de las intervenciones terapéuticas investigadas y de la pregunta que se desea responder con el estudio. En la presente revisión se describen los principales tipos de ensayos clínicos que se realizan en el área de la reumatología, incluyendo sus aplicaciones y limitaciones.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[A B S T R A C T There are different types of clinical trial designs that serve specific purposes, which will depend on the nature of the rheumatological disease, the characteristics of the therapeutic interventions being investigated and the question the study is intended to answer. This review describes the main types of clinical trials conducted in the field of rheumatology, including their applications and limitations.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Ensayo clínico]]></kwd>
<kwd lng="es"><![CDATA[Aleatorización]]></kwd>
<kwd lng="es"><![CDATA[Estudios controlados]]></kwd>
<kwd lng="en"><![CDATA[Clinical trial]]></kwd>
<kwd lng="en"><![CDATA[Randomisation]]></kwd>
<kwd lng="en"><![CDATA[Controlled studies]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Furberg]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[DeMets]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Reboussin]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Introduction to clinical trials]]></article-title>
<source><![CDATA[Fundamentals of Clinical Trials.]]></source>
<year>2010</year>
<page-range>1-23</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[NY Springer New York]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[SR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical trial structures]]></article-title>
<source><![CDATA[J Exp Stroke Transl Med]]></source>
<year>2010</year>
<numero>3</numero>
<issue>3</issue>
<page-range>8-18</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Koning]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Schalkwijk]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[van der Ven-Jongekrijg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stoffels]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van der Meer]]></surname>
<given-names><![CDATA[JWM]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome]]></article-title>
<source><![CDATA[Ann Rheum Dis.]]></source>
<year>2013</year>
<numero>72</numero>
<issue>72</issue>
<page-range>1634-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[DL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Study design. En: Clinical Epidemiology &amp; Evidence-Based Medicine. Fundamental Principles of Clinical Reasoning &amp; Research]]></article-title>
<source><![CDATA[Sage Publications]]></source>
<year>2001</year>
<page-range>147-70</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Capurro]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Gabrielli]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Letelier]]></surname>
<given-names><![CDATA[SLM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importancia de la intención de tratar y el seguimiento en la validez interna de un estudio clínico randomizado]]></article-title>
<source><![CDATA[Rev Med Chil]]></source>
<year>2004</year>
<numero>132</numero>
<issue>132</issue>
<page-range>1557-60</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina Arias]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa Sangrador]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ensayo clínico (III). Aleatorización]]></article-title>
<source><![CDATA[Enmascaramiento. Evid Pediatr]]></source>
<year>2015</year>
<numero>11</numero>
<issue>11</issue>
<page-range>15</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rothman]]></surname>
<given-names><![CDATA[KJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology in clinical settings]]></article-title>
<source><![CDATA[Epidemiology: An Introduction]]></source>
<year>2012</year>
<edition>2</edition>
<page-range>235-53</page-range><publisher-name><![CDATA[Oxford University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aitken]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Laslett]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Haugen]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
<name>
<surname><![CDATA[Otahal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bellamy]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial]]></article-title>
<source><![CDATA[Osteoarthr Cartil]]></source>
<year>2018</year>
<numero>26</numero>
<issue>26</issue>
<page-range>880-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Choy]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Doré]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hakim]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kitas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2015</year>
<numero>54</numero>
<issue>54</issue>
<page-range>1050-5</page-range><publisher-loc><![CDATA[Oxford ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira-González]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bases para la interpretación de los estudios de no inferioridad: a propósito de los estudios ROCKET-AF RE-LY y ARISTOTLE]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2014</year>
<numero>67</numero>
<issue>67</issue>
<page-range>432-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleischmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mysler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kivitz]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Moots]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b/4, double-blind, head-to-head, randomised controlled trial.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<numero>390</numero>
<issue>390</issue>
<page-range>457-68</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Maciel]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[de Lemos]]></surname>
<given-names><![CDATA[LLP]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Kakehasi]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[EIG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adalimumab in rheumatoid arthritis treatment: A systematic review and meta-analysis of randomized clinical trials.]]></article-title>
<source><![CDATA[Rev Bras Reumatol]]></source>
<year>2013</year>
<numero>53</numero>
<issue>53</issue>
<page-range>419-30</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ginzler]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Dooley]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Aranow]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Buyon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Merrill]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<numero>353</numero>
<issue>353</issue>
<page-range>2219-28</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
